Stockreport

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

Cel-Sci Corporation  (CVM) 
NASDAQ:AMEX Investor Relations: cel-sci.com/investor_relations.html
PDF VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pric [Read more]